Capillary Biomedical is a medical device startup developing technologies for diabetes management. We aim to dramatically simplify glucose monitoring and insulin delivery, reducing the burden on both patients and the overall healthcare system.

Our ultimate goal is a fully-implantable automated insulin delivery system consisting of a long-term continuous glucose monitor, insulin infusion pump and closed-loop control algorithm capable of automatically managing blood glucose. The company is based in Irvine, CA and is a spin-out of the Artificial Pancreas Center at the Sidney Kimmel Medical College of Thomas Jefferson University in Philadelphia, PA.

Capillary Biomedical has licensed underlying technology from Thomas Jefferson University. Together with the University, Capillary Biomedical is developing revolutionary CSII catheters. This new technology would improve the predictability of insulin dosing and enable patients to reliably use one CSII catheter for seven or more days. More consistent and reliable insulin absorption will enable people with diabetes to achieve improved blood glucose control.